Outcomes of a pilot randomized clinical trial testing brief interventions to increase HIV pre-exposure prophylaxis uptake among rural people who inject drugs attending syringe services programs.

Hilary L Surratt, Sarah Brown, Abby L Burton, Will Cranford, Laura C Fanucchi, Christie Green, Stephanie M Mersch, Rebecca Rains, Philip M Westgate
Author Information
  1. Hilary L Surratt: Center on Drug and Alcohol Research, University of Kentucky, 845 Angliana Avenue, #105, Lexington, KY 40508, USA. ORCID
  2. Sarah Brown: Appalachian Regional Healthcare, Barbourville, KY, USA.
  3. Abby L Burton: Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KY, USA.
  4. Will Cranford: Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY, USA.
  5. Laura C Fanucchi: Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY, USA. ORCID
  6. Christie Green: Cumberland Valley District Health Department, Manchester, KY, USA.
  7. Stephanie M Mersch: Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KY, USA.
  8. Rebecca Rains: Knox County Health Department, Barbourville, KY, USA.
  9. Philip M Westgate: Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY, USA.

Abstract

Background: Kentucky is one of seven states with high, sustained rural HIV transmission tied to injection drug use. Expanding access to pre-exposure prophylaxis (PrEP) has been endorsed as a key HIV prevention strategy; however, uptake among people who inject drugs (PWID) has been negligible in rural areas. Syringe services programs (SSPs) have been implemented throughout Kentucky's Appalachian region, providing an important opportunity to integrate PrEP services.
Objectives: The primary objective was to examine preliminary efficacy and effect sizes of the study interventions on PrEP initiation among HIV-negative PWID.
Design: Parallel group randomized controlled trial.
Methods: Eighty participants were enrolled from two rural SSP locations in southeastern Kentucky. Following informed consent, participants completed a baseline interview, and were randomized to the intervention comparators. The primary endpoint was PrEP initiation, measured by dispensed PrEP prescription, within the 6-month study period. Analyses employed intent-to-treat (ITT) and per protocol approaches.
Results: In total, 77/80 enrollees (96.2%) completed at least one session of their assigned intervention, regardless of trial arm. Seventy (87.5%) were linked to the embedded PrEP provider for the initial clinical visit; 38 (47.5%) completed a follow-up clinical visit with the provider, 22 (27.5%) were issued a prescription, and 7 (8.8%) initiated PrEP during the study period. We observed a 12.1% difference (14.6% vs 2.5%; ITT) and 12.8% difference (15.4% vs 2.6%; per protocol) in the primary outcome (PrEP initiation), in favor of the experimental intervention.
Conclusion: This pilot trial established proof of concept for integrated PrEP care within SSPs in rural areas, and demonstrated a clinically meaningful difference in PrEP initiation between interventions, which warrants examination in a larger trial. Rates of early care discontinuation indicate a need for ongoing patient engagement strategies and implementation support for community SSPs.
Trial registration: Prospective registration with ClinicalTrials.gov, NCT05037513 (registered August 5, 2021).

Keywords

Associated Data

ClinicalTrials.gov | NCT05037513

References

  1. AIDS Behav. 2014 Apr;18(4):726-39 [PMID: 24558098]
  2. J Acquir Immune Defic Syndr. 2017 May 1;75(1):35-44 [PMID: 28225437]
  3. Drug Alcohol Depend. 2021 Sep 1;226:108878 [PMID: 34214880]
  4. BMC Health Serv Res. 2010 Aug 20;10:246 [PMID: 20727189]
  5. J Biomed Inform. 2019 Jul;95:103208 [PMID: 31078660]
  6. AIDS Behav. 2024 Jul;28(7):2340-2349 [PMID: 38743381]
  7. J Med Internet Res. 2020 Oct 23;22(10):e23173 [PMID: 33095177]
  8. AIDS Patient Care STDS. 2016 Aug;30(8):379-84 [PMID: 27509238]
  9. Trials. 2014 Jul 03;15:264 [PMID: 24993581]
  10. J Biomed Inform. 2009 Apr;42(2):377-81 [PMID: 18929686]
  11. Sex Transm Dis. 2019 Aug;46(8):507-512 [PMID: 31295217]
  12. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):72-77 [PMID: 28902704]
  13. AIDS Behav. 2012 May;16(4):1075-83 [PMID: 21785873]
  14. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):597-606 [PMID: 18285714]
  15. AIDS Behav. 2020 Aug;24(8):2336-2346 [PMID: 31960197]
  16. Int J Drug Policy. 2021 Sep;95:103255 [PMID: 33853033]
  17. AIDS Care. 2024 Dec;36(12):1858-1868 [PMID: 39137923]
  18. BMC Public Health. 2020 Feb 18;20(1):248 [PMID: 32070318]
  19. Clin Transl Sci. 2011 Oct;4(5):332-7 [PMID: 22029804]
  20. Curr HIV/AIDS Rep. 2018 Jun;15(3):245-254 [PMID: 29796965]
  21. JAMA. 2023 Jan 24;329(4):336-337 [PMID: 36692577]
  22. Lancet HIV. 2021 Feb;8(2):e114-e120 [PMID: 33128874]
  23. HIV Med. 2023 Mar;24 Suppl 2:8-19 [PMID: 36920412]
  24. Am J Public Health. 2020 Jan;110(1):34-36 [PMID: 31800272]
  25. AIDS Behav. 2021 May;25(5):1490-1506 [PMID: 32749627]
  26. Transl Behav Med. 2014 Sep;4(3):260-74 [PMID: 25264466]
  27. Ann Epidemiol. 2018 Dec;28(12):841-849 [PMID: 29983236]
  28. JAMA Netw Open. 2022 Jul 1;5(7):e2221352 [PMID: 35819788]
  29. AIDS Educ Prev. 2017 Aug;29(4):315-329 [PMID: 28825858]
  30. JAMA. 2023 Aug 22;330(8):736-745 [PMID: 37606666]
  31. Harm Reduct J. 2018 Nov 12;15(1):55 [PMID: 30419926]
  32. Am J Prev Med. 2021 Nov;61(5 Suppl 1):S118-S129 [PMID: 34686281]
  33. BMJ. 2016 Oct 24;355:i5239 [PMID: 27777223]
  34. Am J Public Health. 2020 Jan;110(1):22-24 [PMID: 31725312]
  35. BMC Infect Dis. 2022 Sep 14;22(1):737 [PMID: 36104676]
  36. J Trauma Stress. 2007 Dec;20(6):1019-28 [PMID: 18157881]
  37. Harm Reduct J. 2022 Dec 3;19(1):133 [PMID: 36463183]
  38. Infect Dis Clin North Am. 2020 Sep;34(3):xiii-xiv [PMID: 32782107]
  39. JAMA Netw Open. 2022 Jul 1;5(7):e2221346 [PMID: 35819784]
  40. AIDS Behav. 2020 Jun;24(6):1942-1950 [PMID: 31853771]
  41. AIDS Behav. 2017 Apr;21(4):1025-1033 [PMID: 27896552]
  42. AIDS. 2017 Mar 13;31(5):731-734 [PMID: 28060019]
  43. J Int AIDS Soc. 2019 May;22(5):e25286 [PMID: 31111684]
  44. Lancet. 2019 Nov 2;394(10209):1652-1667 [PMID: 31668409]
  45. Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269 [PMID: 31177363]
  46. J Infect Dis. 2019 Jul 2;220(3):346-349 [PMID: 30941402]
  47. Open Forum Infect Dis. 2019 Jun 27;6(7):ofz310 [PMID: 31341933]
  48. Health Qual Life Outcomes. 2017 May 30;15(1):115 [PMID: 28558805]
  49. PLoS One. 2020 Apr 16;15(4):e0231424 [PMID: 32298320]
  50. Curr HIV/AIDS Rep. 2021 Dec;18(6):500-507 [PMID: 34708316]
  51. Am J Public Health. 2019 Sep;109(9):1216-1223 [PMID: 31318587]
  52. Ann Epidemiol. 2021 Dec;64:102-110 [PMID: 34563567]
  53. J Int AIDS Soc. 2016 Dec 01;19(1):21484 [PMID: 27914186]
  54. JAMA. 2023 Jan 3;329(1):63-84 [PMID: 36454551]
  55. AIDS. 2019 Jul 15;33(9):1467-1476 [PMID: 30964750]
  56. J Gen Intern Med. 2023 Mar;38(4):913-921 [PMID: 35614171]
  57. Drug Alcohol Depend. 2007 Nov;91 Suppl 1:S4-17 [PMID: 17582705]
  58. Subst Abuse Rehabil. 2011 Nov 22;2:205-18 [PMID: 24474858]
  59. J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):e61-e70 [PMID: 33148998]
  60. AIDS. 2005 Mar 4;19(4):423-31 [PMID: 15750396]
  61. JAMA Netw Open. 2023 Aug 1;6(8):e2330225 [PMID: 37603331]
  62. AIDS Behav. 2021 May;25(5):1411-1422 [PMID: 32748159]
  63. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):323-331 [PMID: 27763996]
  64. Drug Alcohol Depend. 2008 Apr 1;94(1-3):172-82 [PMID: 18242883]
  65. Stat Methods Med Res. 2016 Jun;25(3):1057-73 [PMID: 26092476]
  66. Front Psychiatry. 2022 May 30;13:905314 [PMID: 35706473]
  67. J Acquir Immune Defic Syndr. 2008 Mar 1;47 Suppl 1:S40-6 [PMID: 18301133]

Grants

  1. R34 DA053140/NIDA NIH HHS
  2. UL1 TR001998/NCATS NIH HHS

Word Cloud

Created with Highcharts 10.0.0PrEPruraltrialHIVinterventionsinitiation5%pre-exposureprophylaxisamongpeopleinjectdrugsservicesSSPsprimarystudyrandomizedcompletedinterventionclinicaldifferenceKentuckyonepreventionuptakePWIDareasprogramsparticipantsprescriptionwithinperiodITTperprotocolprovidervisit8%126%vs2pilotcareBackground:sevenstateshighsustainedtransmissiontiedinjectiondruguseExpandingaccessendorsedkeystrategyhowevernegligibleSyringeimplementedthroughoutKentucky'sAppalachianregionprovidingimportantopportunityintegrateObjectives:objectiveexaminepreliminaryefficacyeffectsizesHIV-negativeDesign:ParallelgroupcontrolledMethods:EightyenrolledtwoSSPlocationssoutheasternFollowinginformedconsentbaselineinterviewcomparatorsendpointmeasureddispensed6-monthAnalysesemployedintent-to-treatapproachesResults:total77/80enrollees962%leastsessionassignedregardlessarmSeventy87linkedembeddedinitial3847follow-up2227issued78initiatedobserved1%14154%outcomefavorexperimentalConclusion:establishedproofconceptintegrateddemonstratedclinicallymeaningfulwarrantsexaminationlargerRatesearlydiscontinuationindicateneedongoingpatientengagementstrategiesimplementationsupportcommunityTrialregistration:ProspectiveregistrationClinicalTrialsgovNCT05037513registeredAugust52021Outcomestestingbriefincreaseattendingsyringeharmreductionstrengths-based

Similar Articles

Cited By